NCT06188338

A 56-day Clinical Study on Facial Skin Rejuvenation

Clinical Study on 56-Day Continuous Improvement of 1064nm Fractional Picosecond Laser Treatment With Formulations of A Proprietary Anti-aging Complex Composition

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Botanee Group Co., Ltd. · Industry
• Sex: Female
• Age: 30 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This clinical trial aims to learn about the efficacy of MLYAAT-1002® (a proprietary anti-aging complex, MLYAAT is short for "multi-layer anti-ageing technology" ) in female subjects who have newly received the rejuvenation treatment by comparing visual clinical scores, skin attributes measurement and image analysis.

Detailed description

The main expectations are: * After the 8-week continuous use of the test formulations with MLYAAT-1002® on one split-face side, the clinical manifestations and scores of photoaging improve compared to those of the control side using the placebo formulations. * After the 8-week continuous use of the test formulations with MLYAAT-1002®, indicators of skin tone, individual type angle (ITA), CIELAB color space, pores and wrinkles improve compared to those of the control side using the placebo formulations.

Conditions

• Skin Manifestations
• Wrinkle
• Photoaging

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.	Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.
COMBINATION_PRODUCT	Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®	Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.

Timeline

• Start date: 2023-11-18
• Primary completion: 2024-01-27
• Completion: 2024-08-15
• First posted: 2024-01-03
• Last updated: 2024-08-16

Locations

1 site across 1 country: China